Abstract
Caliskan et al. in their retrospective analysis compared the outcomes of 66 patients with C3 glomerulopathy who were treated with mycophenolate mofetil, with cyclophosphamide-based treatment, or by adopting conservative treatment methods. The primary outcome (chronic kidney disease stage 5 or decrease of estimated glomerular filtration rate [eGFR] by more than 50%) was not significantly different between the groups with 25.8% of patients achieving the primary outcome within the median follow-up of 28 months.
Numerically the percentage of patients achieving the primary outcome was similar among mycophenolate-treated patients and patients on conservative treatment (29.6 vs. 31.3%, respectively). Clinical predictors of poor outcome were young age, higher proteinuria, and lower eGFR at presentation.
With regard to the histology, poor outcome was related to the percentage of crescentic and sclerotic glomeruli and to the severity of interstitial fibrosis.